BML, Inc. (MUN:BMZ)

Market Cap	799.33M +17.0%
Revenue (ttm)	849.17M +5.9%
Net Income	40.64M +15.6%
EPS	1.05 +16.2%
Shares Out	n/a
PE Ratio	19.67
Forward PE	n/a
Dividend	0.77 (3.65%)
Ex-Dividend Date	Sep 29, 2025

Volume	n/a
Average Volume	n/a
Open	21.20
Previous Close	21.20
Day's Range	21.20 - 21.20
52-Week Range	16.40 - 21.40
Beta	n/a
RSI	55.23
Earnings Date	Feb 6, 2026

About BML, Inc.

BML, Inc. provides contract clinical testing and related services in Japan. The company offers a range of laboratory testing, such as biochemical and hematologic examination; laboratory test, including tumor markers, infectious diseases, hormones, cellular immunity, genetics, bacteriological tests, and other test; specialized testing in oncology, infectious diseases, diabetes, hypertension, allergies, genetics, and more areas, as well as develops Frontier and Symphony automation systems, which automate pre-testing from specimen sorting to dispe...

• Industry: Commercial Physical and Biological Research
• Founded: 1955
• Employees: 4,558
• Stock Exchange: Munich Stock Exchange
• Ticker Symbol: BMZ

Financial Performance

In fiscal year 2025, BML, Inc.'s revenue was 143.19 billion, an increase of 3.79% compared to the previous year's 137.96 billion. Earnings were 6.26 billion, an increase of 3.80%.

Financial numbers in JPY